Carlo Bosi: Out on European Journal Of Cancer ‘Pan-cancer analysis of antibody-drug conjugate targets and putative predictors of treatment response’
Carlo Bosi, Medical oncology resident in Ospedale San Raffaele, shared a post on X/Twitter:
“Out on European Journal Of Cancer ‘Pan-cancer analysis of antibody-drug conjugate targets and putative predictors of treatment response’
We searched clinicaltrials.gov for trials testing ADCs in solid tumors, and annotated them by ADC targets (n=54), type of payload and disease condition.
We investigated the mRNA expression of ADC targets and genes potentially implicated in treatment response/resistence to ADCs in large publicly available datasets
We assessed ADC target expression compared to healthy tissue across solid tumors. Tumor types with the highest ADCs target expression may represents unexplored opportunities for ADCs development
Metastases differed from primary tumors in expression of ADC targets, and this should be taken into account
Potential, not clinically proven, predictors of ADCs response/resistence (e.g. cathepsins, genes implied in cellular trafficking or sensitivity to cytotoxic cargo) are heterogeneously expressed, suggesting a different intrinsic sensitivity to ADCs
Breast cancer subtypes share most, but not all, ADC targets expression, which may pave the way for novel therapeutic opportunities, e.g. targeting ITGB6 and LRRC15 in HER2+ breast cancers
ADC targets with the highest differential expression compared to normal tissues may contribute to orient the development of ADCs in clinical trials
There is substantial inter-patient heterogeneity in ADC targets expression. This might be considered when multiple ADCs options, including agnostic registrations, are available in the clinic
Huge thanks to my mentor Giampaolo Bianchini Matteo Dugo co-lead of the study, the invaluable support of AirC and Ospedale San Raffaele, and the contributions of all the other co-authors, Aron Bartha, Barbara Galbardi, Giulia Notini, Matteo M. Naldini, Luca Licata, Giulia Viale“
For details click here.
Source: Carlo Bosi/Twitter
-
17:28 29/11JeeSuk Chang: A multi-center trial - great efforts from the KROG team
-
17:00 29/11Maite Bourlon: Access to novel drugs for metastatic renal cell carcinoma is an unmet need in the Mexican population
-
23:17 28/11Manni Mohyuddin: Current trials must have observation/surveillance as control arm
-
23:04 28/11Juan P. Alderuccio: Our approach to secondary CNS involvement by aggressive lymphomas
-
17:17 27/11Vivek Subbiah: Treatment patterns and overall survival (OS) in patients with advanced NSCLC in three countries between 2011 and 2020
-
17:43 28/11Michele Carbone: The world is full of good, honest, nice people
-
17:24 28/11Jessica Clerc: Celebrating 90 Years of Excellence and Dedication in Cancer Care!
-
17:44 25/11Carlos Pedraz: Congratulations, Dr. Rafael Rosell for the very well deserved 2023 ISLB Lifetime Achievement Award
-
17:10 25/11100 Influential Celebrities in Oncology: The 2023 Edition – Part 4
-
13:34 24/11"Bald for a Cause" initiative - UWC Dilijan College
-
17:34 28/11The International Association of Cancer Registries annual conference - IARC
-
18:05 26/11Submit your abstract by 13 February for ESMO-Breast-24 - ESMO
-
17:58 26/11Lisa A. Lacasse: My sincere gratitude to the ACS CAN team, our incredible volunteers, and supporters for another outstanding year
-
16:47 16/11How social determinants can influence a patient’s ability to stay in treatment - ASCO
-
13:22 16/11SIOP Europe Student Summer School for Paediatric Oncology
-
17:25 29/11NIH Director’s Early Independence Award supports junior scientists to launch independent careers - National Cancer Institute
-
17:07 29/11Santhosh Kumar Devadas: I’m starting a new position as a Professor of Medical Oncology and Chief of Bone Marrow Transplant at Ramaiah Memorial Hospital and Ramaiah Medical College
-
16:48 27/11CRCHD seeks motivated scientists to serve as Program Directors - NCI Disparities
-
16:25 27/11Luisa Basset completed a fruitful nine-year tenure on the CCI board of trustees - Childhood Cancer International
-
18:14 26/11Tristan Knight: Attention hematology / oncology and pediatric hematology / oncology fellows